Built to help voters quickly verify how officials vote — district first, party second. All information is sourced from official public records.
HR. 950 · 119th Congress

Saving Seniors Money on Prescriptions Act

In committee

This bill has not become law. Status shown reflects the latest official action.

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Bill details

Introduced: 2/4/2025
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill ID: 119hr950
Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary

Introduced in House

Saving Seniors Money on Prescriptions Act This bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs. Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations. In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

Source: BILLSUM · Summary date: 2/4/2025

District impact notes

0 notes

No impact notes have been generated for this bill yet.

These impact notes are AI-generated from official bill metadata/summary as a prototype feature — not official government language.

Tip: impacts are typically generated by the scheduled workflow. If you just ran it, refresh in a minute.

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. (No interpretation.)

Summary source label: BILLSUM
About this data
  • OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
  • Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
  • District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
  • This page updates automatically via a daily ingestion pipeline.

About this data

Non-partisan by design
OurCongress provides plain-English context without endorsements, political interpretation, or advocacy.
Official sources
Data is sourced from official government records (e.g., Congress.gov, GovInfo, Clerk of the House, and the U.S. Senate).
AI-generated text
Some sections may be AI-generated from official summaries/metadata to help readability. AI output can be imperfect—verify with primary sources.
Last updated: 2/4/2025Source: BILLSUMBill: 119hr950Learn more →